| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Jeffrey A Lieberma. Dopamine partial agonists: a new class of antipsychotic. CNS drugs. vol 18. issue 4. 2004-05-10. PMID:15015905. |
in conclusion, the findings from clinical studies of aripiprazole show that dopamine partial agonists offer a novel, effective and well-tolerated treatment approach for patients with schizophrenia. |
2004-05-10 |
2023-08-12 |
Not clear |
| Siegfried Kasper, Mark N Lerman, Robert D McQuade, Anutosh Saha, William H Carson, Mirza Ali, Donald Archibald, Gary Ingenito, Ronald Marcus, Teresa Pigot. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. The international journal of neuropsychopharmacology. vol 6. issue 4. 2004-05-06. PMID:14609439. |
efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. |
2004-05-06 |
2023-08-12 |
Not clear |
| Siegfried Kasper, Mark N Lerman, Robert D McQuade, Anutosh Saha, William H Carson, Mirza Ali, Donald Archibald, Gary Ingenito, Ronald Marcus, Teresa Pigot. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. The international journal of neuropsychopharmacology. vol 6. issue 4. 2004-05-06. PMID:14609439. |
aripiprazole is a novel atypical antipsychotic for the treatment of schizophrenia. |
2004-05-06 |
2023-08-12 |
Not clear |
| Siegfried Kasper, Mark N Lerman, Robert D McQuade, Anutosh Saha, William H Carson, Mirza Ali, Donald Archibald, Gary Ingenito, Ronald Marcus, Teresa Pigot. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. The international journal of neuropsychopharmacology. vol 6. issue 4. 2004-05-06. PMID:14609439. |
the long-term efficacy and safety of aripiprazole (30 mg/d) relative to haloperidol (10 mg/d) were investigated in two 52-wk, randomized, double-blind, multicentre studies (using similar protocols which were prospectively identified to be pooled for analysis) in 1294 patients in acute relapse with a diagnosis of chronic schizophrenia and who had previously responded to antipsychotic medications. |
2004-05-06 |
2023-08-12 |
Not clear |
| Siegfried Kasper, Mark N Lerman, Robert D McQuade, Anutosh Saha, William H Carson, Mirza Ali, Donald Archibald, Gary Ingenito, Ronald Marcus, Teresa Pigot. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. The international journal of neuropsychopharmacology. vol 6. issue 4. 2004-05-06. PMID:14609439. |
aripiprazole represents a promising new option for the long-term treatment of schizophrenia. |
2004-05-06 |
2023-08-12 |
Not clear |
| S M Stahl, M M Grad. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Current medicinal chemistry. vol 11. issue 3. 2004-04-20. PMID:14965234. |
the atypical antipsychotics risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole have become first-line treatment for schizophrenia because they reduce the positive symptoms of psychosis but do not have a high incidence of extrapyramidal symptoms. |
2004-04-20 |
2023-08-12 |
Not clear |
| Elizabeth Winan. Aripiprazole. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. vol 60. issue 23. 2004-03-19. PMID:14686220. |
aripiprazole is a third-generation antipsychotic agent indicated for use in the treatment of schizophrenia. |
2004-03-19 |
2023-08-12 |
Not clear |
| Elizabeth Winan. Aripiprazole. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. vol 60. issue 23. 2004-03-19. PMID:14686220. |
in controlled, randomized, multicenter trials, aripiprazole has demonstrated efficacy in the treatment of schizophrenia comparable to that of haloperidol and superior to placebo. |
2004-03-19 |
2023-08-12 |
Not clear |
| Elizabeth Winan. Aripiprazole. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. vol 60. issue 23. 2004-03-19. PMID:14686220. |
aripiprazole offers an alternative to second-generation antipsychotic agents in the treatment of schizophrenia. |
2004-03-19 |
2023-08-12 |
Not clear |
| James P Kellehe. Aripiprazole is effective against the symptoms of schizophrenia and schizoaffective disorder. Evidence-based mental health. vol 7. issue 1. 2004-03-01. PMID:14769657. |
aripiprazole is effective against the symptoms of schizophrenia and schizoaffective disorder. |
2004-03-01 |
2023-08-12 |
Not clear |
| Teresa A Pigott, William H Carson, Anutosh R Saha, Anne F Torbeyns, Elyse G Stock, Gary G Ingenit. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. The Journal of clinical psychiatry. vol 64. issue 9. 2004-02-17. PMID:14628980. |
aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. |
2004-02-17 |
2023-08-12 |
Not clear |
| Teresa A Pigott, William H Carson, Anutosh R Saha, Anne F Torbeyns, Elyse G Stock, Gary G Ingenit. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. The Journal of clinical psychiatry. vol 64. issue 9. 2004-02-17. PMID:14628980. |
aripiprazole is a novel antipsychotic for the management of schizophrenia. |
2004-02-17 |
2023-08-12 |
Not clear |
| Teresa A Pigott, William H Carson, Anutosh R Saha, Anne F Torbeyns, Elyse G Stock, Gary G Ingenit. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. The Journal of clinical psychiatry. vol 64. issue 9. 2004-02-17. PMID:14628980. |
this study investigated the efficacy, safety, and tolerability of aripiprazole in preventing relapse in adult chronic schizophrenia patients experiencing ongoing stable symptomatology. |
2004-02-17 |
2023-08-12 |
Not clear |
| Stephen R Marder, Robert D McQuade, Elyse Stock, Stephen Kaplita, Ronald Marcus, Allan Z Safferman, Anutosh Saha, Mirza Ali, Taro Iwamot. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophrenia research. vol 61. issue 2-3. 2003-12-09. PMID:12729864. |
aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. |
2003-12-09 |
2023-08-12 |
Not clear |
| Stephen R Marder, Robert D McQuade, Elyse Stock, Stephen Kaplita, Ronald Marcus, Allan Z Safferman, Anutosh Saha, Mirza Ali, Taro Iwamot. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophrenia research. vol 61. issue 2-3. 2003-12-09. PMID:12729864. |
presented here is a pooled analysis of safety and tolerability data from all completed short-term, placebo-controlled trials in schizophrenia from the aripiprazole clinical development program. |
2003-12-09 |
2023-08-12 |
Not clear |
| Stephen R Marder, Robert D McQuade, Elyse Stock, Stephen Kaplita, Ronald Marcus, Allan Z Safferman, Anutosh Saha, Mirza Ali, Taro Iwamot. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophrenia research. vol 61. issue 2-3. 2003-12-09. PMID:12729864. |
data were analyzed from five 4- to 6-week double-blind multicenter studies of patients hospitalized with acute relapse of schizophrenia or schizoaffective disorder randomized to aripiprazole (n=932), placebo (n=416), or haloperidol (n=201). |
2003-12-09 |
2023-08-12 |
Not clear |
| Stephen R Marder, Robert D McQuade, Elyse Stock, Stephen Kaplita, Ronald Marcus, Allan Z Safferman, Anutosh Saha, Mirza Ali, Taro Iwamot. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophrenia research. vol 61. issue 2-3. 2003-12-09. PMID:12729864. |
aripiprazole's safety profile may offer benefits in schizophrenia treatment. |
2003-12-09 |
2023-08-12 |
Not clear |
| Martha Sajatovi. Treatment for mood and anxiety disorders: quetiapine and aripiprazole. Current psychiatry reports. vol 5. issue 4. 2003-12-09. PMID:12857536. |
aripiprazole was recently approved for the treatment of schizophrenia by the us food and drug administration in late 2002, and is being used increasingly in clinical settings. |
2003-12-09 |
2023-08-12 |
Not clear |
| Steven G Potkin, Anutosh R Saha, Mary J Kujawa, William H Carson, Mirza Ali, Elyse Stock, Joseph Stringfellow, Gary Ingenito, Stephen R Marde. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Archives of general psychiatry. vol 60. issue 7. 2003-09-16. PMID:12860772. |
aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. |
2003-09-16 |
2023-08-12 |
Not clear |
| Steven G Potkin, Anutosh R Saha, Mary J Kujawa, William H Carson, Mirza Ali, Elyse Stock, Joseph Stringfellow, Gary Ingenito, Stephen R Marde. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Archives of general psychiatry. vol 60. issue 7. 2003-09-16. PMID:12860772. |
this multicenter trial examined the efficacy, safety, and tolerability of aripiprazole in patients with acute exacerbation of schizophrenia or schizoaffective disorder. |
2003-09-16 |
2023-08-12 |
Not clear |